Company Monitoring Page for Celgene

latest headlines for company on cafepharma

Celgene executives whipped up new, lucrative severance plans ahead of Bristol-Myers megadeal
Fierce Pharma
Sat, 01/5/19 - 12:12 am
Tags:
Bristol-Myers Squibb, Celgene, M&A, severance, executive pay
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss
Fierce Pharma
Fri, 01/4/19 - 11:59 pm
Tags:
Bristol-Myers Squibb, Celgene, M&A, Revlimid, patents
Should Celgene Investors Take Bristol's Money and Run?
Motley Fool
Fri, 01/4/19 - 10:01 am
Tags:
Celgene, Bristol-Myers Squibb, M&A
Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene
Yahoo/Motley Fool
Fri, 01/4/19 - 09:14 am
Tags:
M&A, Celgene, Bristol-Myers Squibb
Bristol-Myers Squibb And Celgene's Big Winner? Los Angeles Billionaire Patrick Soon-Shiong
Forbes
Thu, 01/3/19 - 11:47 pm
Tags:
Patrick Soon-Shiong, Bristol-Myers Squibb, Celgene, M&A
BMS deal weighs on Celgene partners
BioCentury
Thu, 01/3/19 - 11:45 pm
Tags:
M&A, Celgene, Bristol-Myers Squibb, Acceleron, BeiGene
Bristol-Myers to buy Celgene in industry-shaking $74B deal
Biopharma Dive
Thu, 01/3/19 - 09:50 am
Tags:
M&A, Bristol-Myers Squibb, Celgene, immuno-oncology
Celgene invests in Chinese biotech Antengene again
Fierce Biotech
Wed, 01/2/19 - 10:03 am
Tags:
Celgene, Antengene, China
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
Tags:
clinical trials, Takeda, Zinfandel Pharmaceuticals, pioglitazone, Alzheimer's disease, Boehringer Ingelheim, BI 409306, Merck, verubecestat, Celgene, MS, ozanimod, Incyte, ID01, melanoma, vTv Therapeutics, azeliragon, Roche, Tecentriq, Exelixis, colorectal cancer, JNJ, atabacestat, Sareptat Therapeutics, DMD, Exondys 51, Alkermes, ALKS-5461, clinical depression
3 Biotechs With Potential Blockbusters Near the Finish Line
Motley Fool
Tue, 12/18/18 - 12:48 pm
Tags:
Vertex Pharmaceuticals, VX-659 + tezacaftor + ivacaftor, Celgene, JCAR017, Novo Nordisk, semaglutide
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
Tags:
clinical trials, Alzheimer's disease, Biogen, Duchenne Muscular Dystrophy, Pfizer, Solid Biosciences, Sarepta Therapeutics, hemophilia A, Biomarin, Multiple Myeloma, Celgene, Bluebird Bio, Amgen, solid tumors, Bristol-Myers Squibb, Nektar Therapeutics, age-related macular degeneration, Regenxbio, SAGE Therapeutics, MorphoSys
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
Mon, 12/10/18 - 07:07 pm
Tags:
clinical trials, Multiple Myeloma, adaptive trial design, AbbVie, Celgene, Eli Lilly, Genentech, Janssen, Takeda
Can Celgene and bluebird bio Survive a Two-Pronged Attack?
Motley Fool
Wed, 12/5/18 - 11:54 am
Tags:
Celgene, Bluebird Bio, bb21217
Celgene scores at ASH18 with double luspatercept data
Pharmaforum
Mon, 12/3/18 - 10:00 am
Tags:
Celgene, luspatercept, ASH2018
ASH18: CAR-T shows up in early CLL test
Biopharma Dive
Sun, 12/2/18 - 10:47 pm
Tags:
Celgene, CAR-T, CLL, ASH2018, JCAR017
Top Biotech Stocks to Watch at ASH 2018
Yahoo/Motley Fool
Sun, 12/2/18 - 12:37 pm
Tags:
ASH2018, Celgene, Bluebird Bio, Acceleron
Roche’s Tecentriq gets fast review in triple negative breast cancer
Pharmaforum
Tue, 11/13/18 - 09:51 am
Tags:
Roche, Genentech, Tecentriq, Celgene, Abraxane, FDA, triple negative breast cancer
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Fierce Pharma
Thu, 11/8/18 - 09:41 am
Tags:
Bristol-Myers Squibb, AbbVie, Empliciti, FDA, Multiple Myeloma, Celgene, Pomalyst
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Fierce Pharma
Sat, 11/3/18 - 04:05 pm
Tags:
Celgene, Revlimid, Roche, Rituxan, follicular lymphoma
Celgene to launch five new products through to 2020
PM Live
Mon, 10/29/18 - 07:02 pm
Tags:
Celgene, Revlimid, FDA, fedratinib, ozanimod, luspatercept, bb2121, liso-cel

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.